Anti-TPO: The Main Marker of Hashimoto's Thyroiditis and How to Interpret It

Introduction

Anti-TPO antibodies are immunoglobulins directed against thyroid peroxidase, the enzyme that oxidizes iodide in the thyroid follicle. Without that oxidation, hormones cannot be assembled. When antibodies block the enzyme, a chronic autoimmune process begins — Hashimoto's thyroiditis (chronic autoimmune thyroiditis, AIT).

Anti-TPO is the principal marker of Hashimoto. Without it, the diagnosis is not made. But a positive titer alone is not a diagnosis either: antibodies are found in 10–15% of healthy women and 5% of healthy men with no clinical signs and no ultrasound changes (PMID 25172240). This article is about when the test changes management, how to read the titer, and why testing "just in case" is a common mistake.

🌀

What Anti-TPO Measures: Biology and Lab Science

Thyroid peroxidase (TPO) is a membrane enzyme of the thyrocyte. It catalyzes two reactions: oxidation of iodide (I⁻ → I⁰) and attachment of iodine to tyrosine residues in thyroglobulin. This is the central step of T4 and T3 synthesis.

▸The catalytic center of TPO contains a heme group — so iron is a cofactor of the enzyme. With ferritin below 70 ng/mL, TPO functions suboptimally even without antibodies. ▸Hydrogen peroxide (H₂O₂) is required for the oxidation reaction. Selenium, via glutathione peroxidase, quenches excess peroxide. Without selenium, the reaction loses control and damages the tissue. ▸Anti-TPO antibodies bind the catalytic domain and trigger complement-dependent and cell-mediated cytolysis of thyrocytes.

In the lab, anti-TPO is measured by ELISA or chemiluminescent immunoassay (CLIA). The reference range depends on the assay — usually "negative" is < 35 IU/mL. Some labs use different cut-offs (9, 60, 100) — always check the reference on the report.

The relationship between titer and diagnosis is detailed in Caturegli et al. (PMID 25172240): 90–95% of histologically confirmed Hashimoto patients are anti-TPO positive, 70% of postpartum thyroiditis cases, and 80% of primary myxedema. In Graves' disease, anti-TPO is present in 50–80% — but it is not a specific marker for Graves.

🌀

When to Test: Clinical Triggers

Anti-TPO testing is indicated when the result changes management. Specific situations:

▸Fatigue, weight gain, hair loss with normal TSH — to separate subclinical AIT from other causes ▸TSH 4–10 mIU/L — to distinguish autoimmune thyroiditis from transient TSH elevation (stress, illness, recovery from acute thyroiditis) ▸Recurrent pregnancy loss, infertility, IVF preparation — even euthyroid AIT increases miscarriage risk and reduces ART success (PMID 22454398) ▸Diffuse hypoechogenicity and heterogeneity on thyroid ultrasound — confirm autoimmune nature of changes ▸Family history of AIT or Graves' disease — risk stratification ▸3–6 months postpartum — peak of postpartum thyroiditis, which progresses to permanent hypothyroidism in 50% of anti-TPO positive women ▸Before starting amiodarone, lithium, or interferon — known triggers of autoimmune thyroid disease ▸Before/during pregnancy — ATA Guideline (PMID 28056690) recommends anti-TPO screening when TSH is above 2.5 mIU/L in pregnant women

For background on thyroid function and iodine within the cofactor system, see Iodine and Thyroid: 5-Step Protocol.

🌀

How to Interpret the Result: Numbers and Context

The number alone is meaningless. With context, the titer carries prognostic weight:

▸< 35 IU/mL (negative) — autoimmune process not confirmed. If hypothyroidism is present, look for other causes: iodine deficiency, postsurgical, post-radiation, central. ▸35–100 IU/mL (borderline) — monitoring. Repeat at 6–12 months. Ultrasound mandatory. Often this is early subclinical AIT or transient elevation after viral infection. ▸100–500 IU/mL (moderate) — probable AIT. Monitor TSH + fT4 every 6–12 months. Progression prevention: selenium, vitamin D, anti-inflammatory diet. ▸500–1000 IU/mL (high) — AIT clinically confirmed. Prepare for hypothyroidism management. ▸> 1000 IU/mL (very high) — high risk of progression to overt hypothyroidism within 5 years (risk approximately 4–5% per year with normal TSH, up to 12% per year with TSH 2.5–4.5).

Important: the titer level does not correlate with the severity of hypothyroidism. A patient with anti-TPO of 5000 IU/mL may be euthyroid, while a patient with anti-TPO of 150 IU/mL may have overt hypothyroidism. Titer predicts progression risk, not the degree of dysfunction.

🌀

The Full Panel: What to Order Alongside Anti-TPO

An isolated anti-TPO without accompanying markers is half-information. A complete thyroid autoimmune workup includes:

▸Anti-TPO — primary marker of Hashimoto and postpartum thyroiditis ▸Anti-TG (anti-thyroglobulin) — less specific for Hashimoto, but valuable in suspected differentiated thyroid cancer as a marker of tumor/residual tissue after thyroidectomy. Positive in 60–80% of Hashimoto cases, but also in 10% of healthy women. ▸TSI / TRAb (TSH receptor antibodies) — marker of Graves' disease (diffuse toxic goiter), not Hashimoto. Order when hyperthyroidism or orbitopathy is suspected. ▸TSH + free T4 + free T3 — functional picture ▸Thyroid ultrasound — diffuse hypoechogenicity and heterogeneity confirm the autoimmune process when anti-TPO is positive

Minimum diagnostic set: TSH + fT4 + anti-TPO + ultrasound. If TSH is elevated and anti-TPO positive, TRAb is not needed. If TSH is suppressed, TRAb is mandatory for differential diagnosis of Graves vs the thyrotoxic phase of Hashimoto.

🌀

What Is Commonly Missed

▸Ferritin and iron. TPO is an iron-dependent enzyme. Iron deficiency worsens hypothyroidism even at adequate T4 levels. Target ferritin: 70–100 ng/mL, not "within reference range." ▸Vitamin D. Deficiency below 30 ng/mL is associated with higher anti-TPO titers and earlier progression to overt hypothyroidism (PMID 28095983). Target level in AIT: 50–80 ng/mL. ▸Red blood cell selenium. Selenium deficiency is the leading cause of AIT "not responding to standard therapy." ▸T4 → T3 conversion. Many patients on L-thyroxine complain of fatigue at "normal TSH." Often this is impaired conversion — see T4–T3 Conversion and Functional Hypothyroidism. ▸Postpartum thyroiditis. In women with anti-TPO positive during pregnancy, the risk of postpartum thyroiditis is 30–50%. Monitoring TSH + anti-TPO at 3 and 6 months postpartum is mandatory.

🌀

Monitoring: Why Anti-TPO Is Not Retested

Anti-TPO is a static marker. Once elevated, antibodies remain elevated for decades. Antibody dynamics clinically do not change AIT management.

L-thyroxine does not reduce anti-TPO. It compensates hypothyroidism but does not treat the autoimmune process. This must be made clear to the patient: the goal of therapy is not to "zero out the antibodies" but to keep TSH and fT4 in the optimal range and resolve symptoms.

The only intervention with proven impact on titer is selenium 200 mcg/day. Meta-analyses by Toulis et al. (PMID 20230891) and Gärtner et al. (PMID 12390416) showed a 30–40% reduction in anti-TPO over 6 months of selenomethionine or sodium selenite. The effect is not universal — selenium works where deficiency exists. Without measuring RBC selenium, the response cannot be guaranteed.

Other nutraceutical influences (vitamin D, myo-inositol, low-dose naltrexone — detailed in LDN for Hashimoto) are discussed in the literature but rest on less robust evidence.

🌀

When the Test Is NOT Needed

▸Screening in asymptomatic men under 40 with no family history and normal TSH — base rate is 4–5%, downstream management does not change. ▸Repeat testing in already confirmed AIT — antibody dynamics do not change therapy. Exception: assessing response to a 6-month selenium course (optional). ▸"Just in case" with normal TSH, normal fT4, no symptoms, no family history, normal ultrasound — low pretest probability, any result will not change management. ▸Every 3 months "for monitoring" — static marker, frequent testing is wasted spending.

ATA Guideline principle (PMID 22954130): anti-TPO testing is indicated when the result changes patient management. If management will not change, the test is not needed.

🌀

What to Do with Anti-TPO Positive and Normal TSH

This is the most common scenario — subclinical AIT. TSH is normal, fT4 is normal, antibodies are positive, symptoms include fatigue, weight gain, hair loss, cold hands. What to do:

▸Monitor TSH + fT4 every 6–12 months. Progression to overt hypothyroidism: 4–5% per year with anti-TPO positive. Goal: do not miss the moment when L-thyroxine becomes necessary. ▸Thyroid ultrasound every 1–2 years — track nodules and volume changes. ▸Selenium 100–200 mcg/day for 6 months with confirmed RBC selenium deficiency. Anti-TPO recheck optional. ▸Vitamin D to 50–80 ng/mL — cholecalciferol 2000–5000 IU/day. ▸Ferritin to 70–100 ng/mL — iron bisglycinate 25–50 mg if deficient. ▸Anti-inflammatory diet — reduce gluten when celiac or intolerance is confirmed (diagnostically: anti-tTG IgA + total IgA), dairy when sensitivity is confirmed. Without celiac, gluten-free is not mandatory. ▸Stress triggers — cortisol suppresses deiodinases and amplifies the autoimmune process. Sleep 7–9 h, HPA-axis control — see Cortisol and the HPA Axis.

When to start L-thyroxine: TSH > 10 mIU/L unequivocally. TSH 4–10 — individualized, considering symptoms, planned pregnancy, titer level, TSH trajectory over time.

🌀

Caution: Limitations and Pitfalls

▸Isolated anti-TPO positive without ultrasound findings and clinical signs is not a diagnosis of AIT. It is a lab finding. Do not start L-thyroxine based on antibodies alone. ▸Postpartum period. Transient thyrotoxicosis 1–3 months postpartum is often mistaken for Graves. Differentiation: TRAb negative, anti-TPO positive, phase self-limited. Do not start antithyroid drugs. ▸Pregnancy. With anti-TPO positive, miscarriage risk is increased even at euthyroidism. Target TSH in the first trimester: < 2.5 mIU/L. Monitor each trimester and at 3 and 6 months postpartum. ▸Amiodarone, lithium, interferon — provocative drugs. Before initiation — anti-TPO + TSH, during treatment — every 3–6 months. ▸Iodine without cofactor preparation in anti-TPO positive patients worsens the autoimmune process. Selenium for 4–8 weeks first, then iodine. Without preparation, "iodine supplements" flare Hashimoto. ▸Laboratory variability. Different assays yield different absolute values. Compare anti-TPO dynamics only within the same lab.

🌀

Bottom Line

Anti-TPO is the key to diagnosis, not the target of therapy. The test is indicated when the result changes management. An isolated positive without clinical signs and ultrasound is a lab finding, not AIT. Repeat testing in already confirmed AIT is not needed — antibodies are static, dynamics do not change management.

The diagnosis of autoimmune thyroiditis per ATA Guideline (PMID 22954130) is a combination: anti-TPO positive + typical ultrasound pattern (diffuse hypoechogenicity, heterogeneity) + clinical (or subclinical) hypothyroidism. If any one of the three is missing, the diagnosis is not yet established. The goal of AIT management is not to "zero out the antibodies" but to keep TSH and fT4 in the optimal range, control symptoms, and reduce progression risk through systemic cofactors (selenium, iron, vitamin D, anti-inflammatory diet).

🌀

About the Author

I am Dr. Vladimir Pereligyn, endocrinologist and researcher. I specialize in endocrine, metabolic, and autoimmune protocols with a holistic approach and individualized lab diagnostics. Book a consultation — universum.earth/consultation. Daily clinical breakdowns — @md_pereligyn_thyroid.

🌀

Sources

• Caturegli P, De Remigis A, Rose NR. *Hashimoto thyroiditis: clinical and diagnostic criteria.* Autoimmun Rev. 2014. [PMID 25172240](https://pubmed.ncbi.nlm.nih.gov/25172240/)
• Garber JR et al. *Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by AACE and ATA.* Endocr Pract. 2012. [PMID 22954130](https://pubmed.ncbi.nlm.nih.gov/22954130/)
• Toulis KA et al. *Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis.* Thyroid. 2010. [PMID 20230891](https://pubmed.ncbi.nlm.nih.gov/20230891/)
• Gärtner R, Gasnier BC. *Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations.* J Clin Endocrinol Metab. 2002. [PMID 12390416](https://pubmed.ncbi.nlm.nih.gov/12390416/)
• Alexander EK et al. *2017 Guidelines of the American Thyroid Association for Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.* Thyroid. 2017. [PMID 28056690](https://pubmed.ncbi.nlm.nih.gov/28056690/)
• Stagnaro-Green A. *Postpartum thyroiditis.* J Clin Endocrinol Metab. 2002. [PMID 12161491](https://pubmed.ncbi.nlm.nih.gov/12161491/)
• Mazokopakis EE, Papadomanolaki MG et al. *Is vitamin D related to anti-thyroid antibodies in Hashimoto's thyroiditis?* Hell J Nucl Med. 2015. [PMID 28095983](https://pubmed.ncbi.nlm.nih.gov/28095983/)

*This article is for informational purposes only and does not replace a medical consultation. Before starting any supplements, changing medication, or undergoing diagnostic procedures, discuss the plan with your physician.*